Aspirin for primary prevention: Is this the end of the road?

Area of Science:

• Cardiology
• Pharmacology
• Preventive Medicine

Background:

• Aspirin is a long-established cardiovascular drug with clear benefits for secondary prevention.
• Use of aspirin for primary cardiovascular prevention remains controversial due to conflicting trial data and varied clinical guidelines.

Purpose of the Study:

• To review the historical use of aspirin in cardiovascular medicine over the past two decades.
• To analyze recent major randomized control trials (published in 2018) focusing on aspirin's role in primary cardiovascular prevention.
• To provide updated guidance on the contentious issue of aspirin for primary prevention.

Main Methods:

• Review of historical data on aspirin's cardiovascular applications.
• Analysis and synthesis of findings from three significant randomized control trials published in 2018.
• Examination of existing societal guidelines and their recommendations regarding aspirin use.

Main Results:

• High-quality evidence supports aspirin for patients with established cardiovascular disease.
• Conflicting results from numerous trials have led to differing recommendations for primary prevention.
• Recent 2018 trials provide supplementary data to inform the debate on aspirin for primary prevention.

Conclusions:

• The role of aspirin in primary cardiovascular prevention continues to be a subject of debate.
• Recent trials offer crucial data to help clarify aspirin's benefits and risks in at-risk populations.
• Updated guidance is needed to reconcile differing recommendations on aspirin for primary prevention.